Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

Author:

Becker Richard C,Moliterno David J,Jennings Lisa K,Pieper Karen S,Pei Jinglan,Niederman Alan,Ziada Khaled M,Berman Gail,Strony John,Joseph Diane,Mahaffey Kenneth W,Van de Werf Frans,Veltri Enrico,Harrington Robert A

Publisher

Elsevier BV

Subject

General Medicine

Cited by 278 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. A case history in natural product-based drug discovery: discovery of vorapaxar (Zontivity™);Medicinal Chemistry Research;2022-09-02

2. The role of thrombin in the pathogenesis of atherosclerosis and its complications;Kardiologiia;2022-03-31

3. Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events – A Review on Vorapaxar;Current Problems in Cardiology;2021-10

4. Antiplatelet Agents;Burger's Medicinal Chemistry and Drug Discovery;2021-04-26

5. Platelet physiology and pharmacology—relevant considerations for patient care;Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease;2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3